Search Results
Nov 08, 2025, 08:51 ET 레파스 우아한 기술, 우아한 주행을 한결같이 보호하는 5성 안전 등급
패턴을 면밀히 분석해 개발됐다. 사고 데이터에 따르면 차체 하부 손상은 시속 30~70km에서 발생하기 가장 쉬우므로 차체 보강이 절실하다. LEPAS L8은 동남아시아의 긴 우기를 고려하여 물이 600mm 이상 차오른 도로를 안전하게 통과할 수 있도록 설계됐다. 단독 사고 중 20%를 차지하는 차량 전복 상황에 대해서도 종합적인 안전성 검증을 마쳤다. 예를 들어 주력 모델인 LEPAS L8은 2025 체리 인터내셔널 유저 서밋(2025 Chery International User Summit)에서 차체 하부 손상, 깊은 수심 통과, 충돌
More news about: Chery Group
Nov 08, 2025, 05:30 ET Tampil Luar Biasa di Milan Selama Tiga Tahun Berturut-turut, TAILG Hadirkan Tren Baru dalam Solusi Mobilitas Listrik di Pasar Dunia
natrium-ion, energi hidrogen, fitur fast charging, hingga fitur berkendara otonom.Di ajang ini, demo fitur autonomous riding F73L membuat audiens terpukau dengan presisi dan sistem pengendaliannya. TAILG juga mengusung konsep inovasi terbuka dengan bekerja
More news about: TAILG
Nov 08, 2025, 03:29 ET LEPASのエレガント・テクノロジー（Elegant Technology）が、グローバルな五つ星安全基準で、あらゆる優雅な旅路を守る
Technology）は、実際のグローバルな生活シーンに基づいています。事故データによると、30～70km/hでの走行時に車体下部損傷が発生しやすいため、シャーシの重点補強を実施します。東南アジアの長い雨季を考慮し、LEPAS L8は600 mm以上の渡河能力を備え、冠水道路も安全に走行可能です。単独事故の20%を占める横転シナリオについても、包括的な検証を実施しています。2025年Chery国際ユーザー・サミット（2025 Chery International User Summit）では、フラッグシップ・モデルLEPAS L8が車体下部接触、深水走行、衝突横転のデモンストレーションを完遂し、妥協なき安全性能を実証しました。アクティブ・セーフティ・システムと駐車支援システムのフル装備により、エレガントな運転（Elegant Driving）のあらゆる局面で確かな信頼性と制御性を保証します。
More news about: Chery Group
Nov 07, 2025, 17:14 ET Boehringer awarded FDA Commissioner's National Priority Voucher for HERNEXEOS® in HER2 lung cancer
Psychological and Physical Symptoms in Newly Diagnosed Lung Cancer. Health Psychol. 2022 Jun; 41(6): 379–388 Andersen, B. L. et al. Newly diagnosed patients with advanced non-small cell lung cancer: A clinical description of those with moderate to severe depressive symptoms.
More news about: Boehringer Ingelheim
Nov 07, 2025, 17:00 ET Lunai Bioworks schafft es, sowohl primäre als auch metastasierte Bauchspeicheldrüsentumoren in präklinischen humanisierten Modellen komplett zurückzubilden, was einen Durchbruch in der allogenen Krebsimmuntherapie bedeutet
und hat zum ersten Mal gezeigt, dass aus CD34+ hämatopoetischen Stammzellen (HSC) gewonnene dendritische Zellen, die so verändert wurden, dass sie CD40L, CD93 und CXCL13 übermäßig produzieren, eine starke Anti-Tumor-Wirkung in humanisierten Mausmodellen für Bauchspeicheldrüsenkrebs haben. Während in
More news about: Lunai Bioworks Inc.
Nov 07, 2025, 16:49 ET Lunai Bioworks、前臨床のヒト化モデルにおいて、原発および転移性膵臓がんの完全退縮を達成──オールロジェニックがん免疫療法における画期的なブレークスルーを示す
るうえで極めて重要なものとなっている。 今回の新たな論文は、Lunai が以前に発表した研究（Vaccines 2025年7月12日; 13(7):749; doi:10.3390/vaccines13070749）を基盤とするものである。同研究では、ヒト化マウスの膵がんモデルにおいて、CD40L、CD93、CXCL13 を過剰発現させた CD34+ 造血幹細胞（HSC）由来樹状細胞（DC）が強力な抗腫瘍活性を示すことが初めて示された。初期研究では研究用グレードのレンチウイルスベクターを使用していたが、今回の最新報告では、将来的な臨床応用を見据え、設計および製造面を改善しつつ同等の有効性を維持した、最適化された臨床対応型コンストラクトについて記載している。
More news about: Lunai Bioworks Inc.
Nov 07, 2025, 16:07 ET Conheça os procedimentos que são eficazes para melhorar o rosto flácido após perda de peso induzida por medicamentos
characterization of human tissue response to injectable poly-L-lactic acid. Dermatol Surg. 2013 Jun;39(6):915-22. 7. Narins RS, et al. A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant
More news about: Galderma
Nov 07, 2025, 13:38 ET Zoomex Becomes Diamond Sponsor of CCCC Lisbon 2025, Showcasing at Europe's Premier Crypto Event
Lisbon 2025. As a top-tier partner of this year's event, Zoomex will feature its latest brand showcase and immersive interactive experiences at Booth L2, highlighting the theme of "Speed & Trust" to redefine the future of trading.
More news about: Zoomex
Nov 07, 2025, 11:30 ET Ivonescimab HARMONi-A Study Final OS Analysis Results Presented at SITC 2025 with OS HR=0.74
regimen was consistent across all subgroups, showing significant improvement regardless of the presence of brain metastases or EGFR mutations (19Del and L858R) During the 32.5-month follow-up period, the ivonescimab combination regimen demonstrated excellent safety
More news about: Akeso, Inc.
Nov 07, 2025, 10:19 ET Mantle Collaborates with Bybit and Backed to Bring U.S. Equities Onchain, Pioneering Next Trillion-Dollar Wave of Tokenized Assets
Capital Markets This integration marks a major milestone for Mantle, Ethereum's largest ZK proof-powered L2 network. Combining a modular architecture, advanced data availability layer, and low-fee environment, Mantle enables secure, scalable and cost-efficient
More news about: Bybit
Nov 07, 2025, 09:43 ET Mantle Collaborates with Bybit and Backed to Bring U.S. Equities Onchain, Pioneering Next Trillion-Dollar Wave of Tokenized Assets
Markets This integration marks a major milestone for Mantle, Ethereum's largest ZK proof-powered L2 network. Combining a modular architecture, advanced data availability layer, and low-fee environment, Mantle enables secure, scalable and cost-efficient
More news about: Bybit
Nov 07, 2025, 09:05 ET Lunit AI Maps the Tumor-Immune Landscape to Predict Immunotherapy Response and Discover New Antibody Targets at SITC 2025
34 cancer types, the study revealed that while most protein targets showed decreased TIL density within expression regions, select proteins such as PD-L1 and TNFRSF4, displayed positive spatial correlation with lymphocyte infiltration. Notably, FGFR4 expression was linked to increased intra-tumoral lymphocytes
More news about: Lunit
Nov 07, 2025, 09:00 ET HanchorBio Presents Two Late-Breaking Abstracts at the Society for Immunotherapy of Cancer 2025 Demonstrating Best-in-Class Potential of HCB101 in Advanced Cancers
durable disease control as monotherapy and a 100% confirmed partial response rate (6/6) in 2L gastric cancer when combined with ramucirumab and paclitaxel, with additional confirmed responses in 1L TNBC and 2L HNSCC, substantially exceeding historical benchmarks.
More news about: HanchorBio Inc.
Nov 07, 2025, 09:00 ET Diakonos Oncology Presents Promising Preliminary Data from Phase 1 Study of DOC1021 Cell-Based Immunotherapy in Pancreatic Cancer at Society for Immunotherapy of Cancer 40th Annual Meeting
Professor of Medicine-Hematology & Oncology, Barry Stephen Smith Memorial Endowed Professor, and Medical Director of Medical Oncology of the Dan L Duncan Comprehensive Cancer Center at the Baylor College of Medicine. "We are now enrolling a second group of patients where DOC1021 is given after surgery
More news about: Diakonos Oncology
Nov 07, 2025, 08:52 ET Weltweit erste, auf APOC3 abzielende Gen-Editing-Therapie zur Behandlung von Hyperlipidämie
Der Patient, bei dem eine Chylomikronämie diagnostiziert wurde, hatte eine lange Vorgeschichte mit Nüchtern-Triglyceridwerten (TG) von über 12,5 mmol/L und wiederkehrender akuter Pankreatitis. In der Dosiseskalationsstudie für CS-121 sank sein Nüchtern-TG-Spiegel innerhalb von drei Tagen nach einer
More news about: CorrectSequence Therapeutics
Nov 07, 2025, 08:31 ET MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025
In addition to its glycemic effects, vanoglipel significantly decreased plasma ALT levels in subjects with baseline ALT between 40 and 200 U/L. The reduction in ALT was not further enhanced by co-administration with a DPP4 inhibitor, suggesting that vanoglipel monotherapy drives the majority
More news about: MetaVia Inc.
Nov 07, 2025, 08:30 ET Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine
(BRII-179-835-001) were categorized as BRII-179 anti-HBs responders or non-responders based on peak hepatitis B surface antibody (anti-HBs) levels (≥10 IU/L or <10 IU/L, respectively), and subsequently received 48 weeks of elebsiran (100 mg Q4W) plus weekly PEG-IFNα in the ENSURE study. Key
More news about: Brii Biosciences Limited
Nov 07, 2025, 08:26 ET AION UT在澳門正式上市，廣汽深度踐行「澳門ACTION」加速生態出海
UT正式在澳門上市。這款面向全球市場打造的智能生活座駕，造型時尚、空間寬敞，具備領先的智能化和超強的安全品質，為澳門消費者帶來超值體驗。 展會現場，AION UT吸引了眾多觀眾駐足體驗，觀眾對這款車的米蘭時尚大掀背造型以及媲美豪華轎車的舒適駕乘空間表示讚賞，並認為智能語音交互、L2級輔助駕駛系統等豐富的科技配置超出預期。有澳門汽車專業媒體表示，AION UT車型在設計、空間表現和智能化等方面表現突出，契合澳門道路環境以及本地消費者對高品質純電小車的需求，預計將收穫良好的市場反響。 廣汽在本次澳門車展的設計
More news about: GAC
Nov 07, 2025, 08:24 ET La primera terapia de edición genética del mundo dirigida a APOC3 para la hiperlipidemia
El paciente, diagnosticado con quilomicronemia, tenía una larga historia de niveles de triglicéridos (TG) en ayunas superiores a 12,5 mmol/L y pancreatitis aguda recurrente. En el IIT de aumento de dosis para CS-121, su nivel de TG en ayunas disminuyó significativamente dentro de los tres
More news about: CorrectSequence Therapeutics
Nov 07, 2025, 08:05 ET International Tower Hill Mines Files 2025 Third Quarter Financial Results
Alaska. On behalf ofInternational Tower Hill Mines Ltd. (signed) Karl L. HannemanChief Executive Officer This news release is not, and is not to be construed in any
More news about: International Tower Hill Mines Ltd.
Nov 07, 2025, 07:00 ET Alebund Presents Phase 3 Trial Results of AP301 at the American Society of Nephrology (ASN) 2025 Congress
with a least squares mean (LSM) difference of -0.02 mmol/L（95% confidence interval (CI): -0.10, 0.06）[-0.06 mg/dL (95% CI: -0.31, 0.20)]; the upper CI bound of 0.06 mmol/L (0.20 mg/dL) was below the pre-defined non-inferiority margin (NIM) of 0.19 mmol/L (0.59 mg/dL). (see Figure 1)
More news about: Alebund Pharmaceuticals
Nov 07, 2025, 07:00 ET Calumet Reports Third Quarter 2025 Results
the impact of liquidation of inventory layers calculated using the LIFO method; (j) RINs mark-to-market adjustments; (k) RINs incurrence expense; and (l) all extraordinary, unusual or non-recurring items of gain or loss, or revenue or expense. We define Adjusted EBITDA with Tax Attributes
More news about: Calumet, Inc.
Nov 07, 2025, 07:00 ET Enbridge Reports Strong Third Quarter Results, Announces Accretive Investments and Reaffirms 2025 Financial Guidance
Preference Shares, Series L
More news about: Enbridge Inc.
Nov 07, 2025, 06:57 ET GORE ANNOUNCES POSITIVE CLINICAL TRIAL RESULTS OF THE INVESTIGATIONAL GORE® VIABAHN® FORTEGRA VENOUS STENT FOR TREATMENT OF PATIENTS WITH DEEP VENOUS ILIOCAVAL OBSTRUCTION
LAS VEGAS and FLAGSTAFF, Ariz., Nov. 7, 2025 /PRNewswire/ -- W. L. Gore & Associates' medical business (Gore) today announced trial results evaluating the investigational GORE® VIABAHN® FORTEGRA
More news about: W. L. Gore & Associates, Inc. MPD Division
Nov 07, 2025, 06:57 ET NYU Langone Cardiologists Share Leading Research at AHA Scientific Sessions 2025 & Dr. Judith S. Hochman Honored with Research Achievement Award
Harmony R. Reynolds, MD, the Joel E. and Joan L. Smilow Professor of Cardiology and director of NYU Langone's Cardiovascular Clinical Research Center, focuses on MINOCA, myocardial infarction with non-obstructive
More news about: NYU Langone Health